Who
Gregory S. Martini
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kyverna Therapeutics; Chief Financial Officer, Ironwood Pharmaceuticals.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $186K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Jan 2025
- Last trade
- 18 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 May 2026filed 20 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —136,612 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —136,612 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $42K11,457 at $3.66 | filing |
| 24 Feb 2026filed 25 Feb 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $42K11,457 at $3.66 | filing |
| 23 Feb 2026filed 25 Feb 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $40K10,487 at $3.81 | filing |
| 23 Feb 2026filed 25 Feb 2026 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $40K10,487 at $3.81 | filing |
| 11 Aug 2025filed 13 Aug 2025 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1,0631,265 at $0.84 | filing |
| 10 Feb 2025filed 12 Feb 2025 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $21K12,052 at $1.76 | filing |
| 27 Jan 2025filed 29 Jan 2025 | IRWD Ironwood PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —111,111 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.